Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lisata Therapeutics, Inc. on October 14, 2025. The filing serves as a Regulation FD disclosure regarding the issuance of a corporate slide presentation intended for use at investor and industry conferences.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation and does not contain audited financial statements or quarterly results.
Material Changes
No material changes to financial performance or operations are reported in this document. The sole event reported is the release of the corporate presentation attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing incorporates a corporate presentation by reference but explicitly states that the information within Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the text of this 8-K does not contain specific guidance, management commentary, or risk factors; these details are contained within the attached presentation.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Corporate Presentation) for specific business updates, as the 8-K text only references its existence.
- Note that the presentation materials are not legally "filed" and are not subject to the liabilities of Section 18 of the Exchange Act.
- Confirm the company's status as a Delaware corporation trading on the Nasdaq Capital Market under the symbol LSTA.